Clinical trial / 2018
In obese, insulin-resistant men, 12 weeks of nicotinamide riboside supplementation was safe but did not improve insulin sensitivity or glucose metabolism.
Forty sedentary, obese men aged 40-70 years were randomized to receive 12 weeks of nicotinamide riboside (NR, 1000 mg twice daily) or placebo. NR supplementation did not improve insulin sensitivity, endogenous glucose production, glucose disposal, or glucose oxidation. Furthermore, NR had no effect on resting energy expenditure, lipolysis, lipid oxidation, or body composition. No serious adverse events occurred and safety blood tests remained normal.
- Study type
- Randomized, placebo-controlled, double-blind parallel trial
- Who was studied
- 40 healthy, sedentary obese men (BMI > 30 kg/m2, age 40-70 y)
- What was measured
- Insulin sensitivity, substrate metabolism, resting energy expenditure, body composition, and safety
THE PAPER
A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects.
Dollerup OL, Christensen B, Svart M, Schmidt MS, Sulek K, Ringgaard S, Stødkilde-Jørgensen H, Møller N, Brenner C, Treebak JT, Jessen N. Am J Clin Nutr, 2018.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.